- Pfizer promotes 'underappreciated' R&D pipeline
- 1Q EARNINGS: Merck looks to innovation not consolidation
- US Capitol Capsule: Rare disease sector matures; FDA keeping pace?
- All about that (R&D) base: Bristol-Myers and Pfizer 4Q earnings
COMMENT Other Informa Comment
- Profile: Janssen R&D boss on the next big thing in medicine & 'ice bucket' funding
- Profile: The ABPI's reimbursement director on Pfizer, his TicTac salary, and paper mache